Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 168460 participants.
Also called NCT07485283
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 168,460 participants
- Registry
-
NCT07485283 -
2025-524944-37-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07485283. Randomized; no masking; primary purpose prevention. Start 2026-04-28 (actual); primary completion 2029-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
- Acronym
- DAN-ZOSTER
- Condition
- Cardiovascular Disease
- Condition
- Dementia
- Intervention (Biological)
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Lead sponsor
- Tor Biering-Sørensen
- Collaborator
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct07485283- Content hash
4ebc27494e64407ebeaa60b8fe970018383dd2ee3ed1481fe04edac178404c4f